Brief Reports Open access

Sodium-glucose cotransporter 2 inhibition in patients with liver cirrhosis and diabetes: a possible role in ascites control?

Authors

  • Aurelio Seidita – articles in this journal https://orcid.org/0000-0003-4080-2641 Unit of Internal Medicine, “V. Cervello” Hospital, Ospedali Riuniti “Villa Sofia-Cervello”, Palermo; Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo; Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), Palermo, Italy.
  • Francesca Mandreucci – articles in this journal Unit of Internal Medicine, “V. Cervello” Hospital, Ospedali Riuniti “Villa Sofia-Cervello”, Palermo; Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Italy.
  • Mirco Pistone – articles in this journal Unit of Internal Medicine, “V. Cervello” Hospital, Ospedali Riuniti “Villa Sofia-Cervello”, Palermo; Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Italy.
  • Silvia Calderone – articles in this journal https://orcid.org/0009-0008-4004-0150 Unit of Internal Medicine, “V. Cervello” Hospital, Ospedali Riuniti “Villa Sofia-Cervello”, Palermo; Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Italy.
  • Alessandra Giuliano – articles in this journal https://orcid.org/0000-0002-9423-5462 Unit of Internal Medicine, “V. Cervello” Hospital, Ospedali Riuniti “Villa Sofia-Cervello”, Palermo; Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Italy.
  • Marta Chiavetta – articles in this journal Unit of Internal Medicine, “V. Cervello” Hospital, Ospedali Riuniti “Villa Sofia-Cervello”, Palermo; Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Italy.
  • Lydia Giannitrapani – articles in this journal Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo; Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), Palermo; Unit of Internal Medicine, University Hospital of Palermo, Italy.
  • Roberto Citarrella – articles in this journal Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo; Unit of Internal Medicine, University Hospital of Palermo, Italy.
  • Maurizio Soresi – articles in this journal Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo; Unit of Internal Medicine, University Hospital of Palermo, Italy.
  • Anna Licata – articles in this journal https://orcid.org/0000-0003-0383-6121 Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo; Unit of Internal Medicine, University Hospital of Palermo, Italy.
  • Antonio Carroccio – articles in this journal Unit of Internal Medicine, “V. Cervello” Hospital, Ospedali Riuniti “Villa Sofia-Cervello”, Palermo; Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Italy.
  • Stella Compagnoni – articles in this journal Corresponding author Email https://orcid.org/0000-0002-3646-8225 Unit of Internal Medicine, “V. Cervello” Hospital, Ospedali Riuniti “Villa Sofia-Cervello”, Palermo, Italy.
Published
12 November 2024
Section
Brief Reports
DOI
10.4081/itjm.2024.1829

Abstract

The aim of this brief report is to evaluate sodium-glucose cotransporter 2 inhibitors (SGLT2-I) effects on patients with both refractory ascites and type 2 diabetes mellitus (T2D). We consecutively recruited all the diabetic patients with refractory ascites due to decompensated liver cirrhosis admitted between February and May 2023 at the Internal Medicine Unit of the University Hospital of Palermo. Clinical and laboratory data were collected after starting SGLT2-I therapy. SGLT2-I use was associated with a reduction/resolution of ascites and with an improvement in serum albumin and sodium levels and estimated glomerular filtration rate. SGLT2-I might represent a valid therapeutic option in the treatment of patients with refractory ascites and T2D, as already hypothesized by other research groups.

Keywords

References

  1. Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2014;104:297-322. DOI: https://doi.org/10.1016/j.diabres.2014.02.014
  2. Usman MS, Siddiqi TJ, Anker SD, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol 2023;81:2377-87. DOI: https://doi.org/10.1161/circ.148.suppl_1.14614
  3. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 2022;400:757-67. DOI: https://doi.org/10.1016/S0140-6736(22)01429-5
  4. Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388:117-27. DOI: https://doi.org/10.1056/NEJMoa2204233
  5. Bauersachs J, Soltani S. Heart failure: update of the ESC 2023 guidelines. Herz 2023;49:19-21. [Article in German]. DOI: https://doi.org/10.1007/s00059-023-05221-2
  6. Maxson R, Starr J, Sewell J, Lyas C. SGLT2 inhibitors to slow chronic kidney disease progression: a review. Clin Ther 2024;46:e23-8. DOI: https://doi.org/10.1016/j.clinthera.2023.10.014
  7. Zhou P, Tan Y, Hao Z, et al. Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: a systematic review and meta-analysis. Front Endocrinol 2023;14:1144838. DOI: https://doi.org/10.3389/fendo.2023.1144838
  8. Montalvo-Gordon I, Chi-Cervera LA, García-Tsao G. Sodium-glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes. Hepatology 2020;72:1880-2. DOI: https://doi.org/10.1002/hep.31270
  9. Saffo S, Taddei T. SGLT2 inhibitors and cirrhosis: a unique perspective on the comanagement of diabetes mellitus and ascites. Clin Liver Dis 2018;11:141-4. DOI: https://doi.org/10.1002/cld.714
  10. Gao Y, Wei L, Zhang DD, et al. SGLT2 inhibitors: a new dawn for recurrent/refractory cirrhotic ascites. J Clin Transl Hepatol 2021;9:795-7. DOI: https://doi.org/10.14218/JCTH.2021.00418
  11. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021;42:2439-54. DOI: https://doi.org/10.1093/eurheartj/ehab309
  12. Siafarikas C, Kapelios CJ, Papatheodoridi M, et al. Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: beyond their antidiabetic use. Liver Int 2024;44:884-93. DOI: https://doi.org/10.1111/liv.15851
  13. Raza S, Osasan S, Sethia S, et al. A systematic review of sodium-glucose cotransporter 2 (SGLT2) inhibitors and sympathetic nervous system inhibition: an underrated mechanism of cardiorenal protection. Cureus 2022;14:e26313. DOI: https://doi.org/10.7759/cureus.26313
  14. Gerdes C, Müller N, Wolf G, Busch M. Nephroprotective properties of antidiabetic drugs. J Clin Med 2023;12:3377. DOI: https://doi.org/10.3390/jcm12103377
  15. Miyamoto Y, Honda A, Yokose S, et al. Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor. Clin Kidney J 2021;15:831-3. DOI: https://doi.org/10.1093/ckj/sfab266
  16. Mazer CD, Hare GMT, Connelly PW, et al. Effect of empagliflozin on erythropoietin levels, iron stores and red blood cell morphology in patients with type 2 diabetes and coronary artery disease. Circulation 2019;141:704-7. DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.044235
  17. Ghanim H, Abuaysheh S, Hejna J, et al. 2020. Dapagliflozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab 2020;105:e1056-63. DOI: https://doi.org/10.1210/clinem/dgaa057

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2024 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.